In particular, we identified patients with the progesterone receptor-negative subtype of HGSOC, characterized by an increased level of miR-16-5p, miR-17-5p, miR-93-5p and miR-20a-5p in peripheral blood, by lower serum CA-125 levels, smaller tumor size, suboptimal cytoreduction in 61.5% of cases and a complete response to adjuvant chemotherapy in only 20% of cases, in comparison with the progesterone receptor-positive subtype of HGSOC, with optimal cytoreduction in 71.4% of cases and a complete response to adjuvant chemotherapy in 85.7% of cases. The gene discussed is MUC16; the disease is neoplasm.